| Multinational Observational Study to Describe Diagnostic Stage Shift in Patients With Lung Cancer Using Medical Records (NCT06842056) | AstraZeneca | 2027-04-01 |
| Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea (NCT06998095) | AstraZeneca | 2026-11-28 |
| Study to Characterise Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Anifrolumab Administered Subcutaneously (SC) or Intravenously (IV) (NCT07688980) | AstraZeneca | 2026-10-30 |
| Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05) (NCT07711002) | AstraZeneca | 2026-10-01 |
| Saphnelo Use in Females of Child-bearing Potential (NCT07431775) | AstraZeneca | 2026-10-01 |
| A Phase IIIb Study to Investigate the Effect of Baxdrostat in Chinese Participants With Uncontrolled Hypertension. (NCT07686120) | AstraZeneca | 2026-09-30 |
| A Multicenter Observational PMS Study Assessing Durvalumab Safety in Indian Adults With Resectable NSCLC (NCT07760519) | AstraZeneca | 2026-09-30 |
| SHIELD: Surveillance of HR+/HER2- : Implementing ESR1m Long-term Monitoring and Detection in 1L aBC (NCT07701070) | AstraZeneca | 2026-09-30 |
| A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholesterolaemia (NCT07619118) | AstraZeneca | 2026-09-15 |
| A Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Mod-severe Systemic Lupus Erythematosus (NCT07751848) | AstraZeneca | 2026-09-04 |
| Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment (NCT07691970) | AstraZeneca | 2026-09-01 |
| Long-term Safety of Eplontersen Treated aTTR Patients and in Liver Transplant and Severely Hepatic Impaired Subpopulations (NCT07654855) | AstraZeneca | 2026-09-01 |
| A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD) (NCT07624305) | AstraZeneca | 2026-09-01 |
| Lung Cancer Screening Implementation Project in the Brazilian Public Health Care System (LUSIP) (NCT07279948) | AstraZeneca | 2026-08-31 |
| A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF (NCT07761117) | AstraZeneca | 2026-08-28 |
| A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease. (NCT07753993) | AstraZeneca | 2026-08-28 |
| A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6). (NCT07735637) | AstraZeneca | 2026-08-25 |
| A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients. (NCT07619131) | AstraZeneca | 2026-08-17 |
| Impact of GDMT in Uncontrolled Asthma Patients Receiving MHD Inhaled Corticosteroids + Long-acting β2 Agonist (NCT07718724) | AstraZeneca | 2026-08-15 |
| A Real-world Study Observing Treatment Patterns and Clinical Results for Patients in China With Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer. (NCT07743944) | AstraZeneca | 2026-08-05 |
| Observational Study That Will Analyse the Spread and Stratification of Lung Cancer Risk Using Artificial Intelligence (NCT07617636) | AstraZeneca | 2026-07-31 |
| BREZTRI REGULATORY POST MARKETING SURVEILLANCE IN KOREA (NCT07570394) | AstraZeneca | 2026-07-31 |
| Investigating the Effect of Itraconazole on the Pharmacokinetics of AZD4144 in Healthy Participants (NCT07685600) | AstraZeneca | 2026-07-30 |
| A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus Erythematosus (NCT07630714) | AstraZeneca | 2026-07-28 |
| A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants (NCT07723833) | AstraZeneca | 2026-07-27 |
| An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC (NCT07720284) | AstraZeneca | 2026-07-16 |
| BEYOND Study: A Multicentre, Prospective, Observational Study of Real-world Treatment Patterns and Outcomes of Trastuzumab Deruxtecan in Patients With HR Positive, HER2-low or Ultra-low Metastatic Breast Cancer Previously Treated With Endocrine Therapy (NCT07597993) | AstraZeneca | 2026-07-12 |
| A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma (NCT07681596) | AstraZeneca | 2026-07-09 |
| A Study to Characterize the Safety and Immunogenicity of AZD6489 in Participants 60 Years of Age and Older (ARIES) (NCT07717840) | AstraZeneca | 2026-07-08 |
| A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin (NCT07664553) | AstraZeneca | 2026-07-08 |
| A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin (NCT07662135) | AstraZeneca | 2026-07-06 |
| A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus (NCT07662109) | AstraZeneca | 2026-07-06 |
| A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus (NCT07662044) | AstraZeneca | 2026-07-06 |
| A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus (NCT07662213) | AstraZeneca | 2026-07-06 |
| Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM (NCT07690436) | AstraZeneca | 2026-07-02 |
| CHARM Hepatocellular Carcinoma MEA Study (NCT07650773) | AstraZeneca | 2026-06-30 |
| PROLONG (PRostateOLaparibONcombinationGcc) Study (NCT07674121) | AstraZeneca | 2026-06-30 |
| Human ADME Study of [14C]-AZD1390 (NCT07643870) | AstraZeneca | 2026-06-30 |
| Observational Study of Natural History of BAG3 Gene Mutation-Associated Dilated Cardiomyopathy in Chinese Adults (NCT07646600) | AstraZeneca | 2026-06-29 |
| A Study to Evaluate the Safety and Pharmacokinetics of AZD7760 in Healthy Japanese Adults (NCT07612813) | AstraZeneca | 2026-06-29 |
| The DEBATE Study "DEvelopment of Endotype-based Biomarkers for the Monitoring of Greek pATiEnts With CRSwNP" (NCT07663409) | AstraZeneca | 2026-06-29 |
| A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM (NCT07667803) | AstraZeneca | 2026-06-29 |
| Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT (NCT07764978) | AstraZeneca | 2026-06-26 |
| Ravulizumab Outcomes in Polish Patients With aHUS (NCT07399730) | AstraZeneca | 2026-06-24 |
| An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer. (NCT07357597) | AstraZeneca | 2026-06-24 |
| Real-World Outcomes of Resected EGFR-Mutated NSCLC Patients Treated With Adjuvant EGFR-TKI in China (NCT07593248) | AstraZeneca | 2026-06-22 |
| A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer (NCT07647328) | AstraZeneca | 2026-06-15 |
| TROP2 NMR Concordance Study (NCT07624318) | AstraZeneca | 2026-06-15 |
| A Phase IIb Study to Evaluate AZD8965 in Participants With IPF. (NCT07652658) | AstraZeneca | 2026-06-11 |
| A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM (NCT07608354) | AstraZeneca | 2026-06-11 |
| Prospective, Non-interventional Single-arm Study With Tezepelumab to Investigate the Change in Clinical and Patient-reported Outcomes in Patients With CRSwNP in Real-world (PETRICHOR) (NCT07633158) | AstraZeneca | 2026-06-10 |
| Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis (NCT07516184) | AstraZeneca | 2026-06-10 |
| A Phase I, Cross-over Study Comparing the Relative Bioavailability of Laroprovstat Plus Ezetimibe Fixed Combination Drug Products Versus Their Single Therapy Products in Healthy Adults (NCT07622433) | AstraZeneca | 2026-06-10 |
| Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab (NCT07024706) | AstraZeneca | 2026-06-04 |
| Anifrolumab Pregnancy Study (NCT07049653) | AstraZeneca | 2026-06-04 |
| Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer (NCT07590934) | AstraZeneca | 2026-06-03 |
| A Study of MET Concordance and Gene Profiling in 1L NSCLC (Genomet) (NCT07613424) | AstraZeneca | 2026-06-02 |
| Barriers and Facilitators of Persistence With Adjuvant Osimertinib (NCT07542210) | AstraZeneca | 2026-06-01 |
| Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC. (NCT07279935) | AstraZeneca | 2026-05-26 |
| Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment (NCT07444567) | AstraZeneca | 2026-05-25 |
| HER2-positive Metastatic Breast Cancer in Kazakhstan (NCT07593196) | AstraZeneca | 2026-05-19 |
| First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer (NCT07529717) | AstraZeneca | 2026-05-18 |
| Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis (NCT07610837) | AstraZeneca | 2026-05-07 |
| A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies (NCT07606066) | AstraZeneca | 2026-05-06 |
| Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer (NCT07427394) | AstraZeneca | 2026-05-06 |
| Long-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of Exacerbations (NCT07566195) | AstraZeneca | 2026-05-05 |
| Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV) (NCT07509151) | AstraZeneca | 2026-05-05 |
| AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01) (NCT07611110) | AstraZeneca | 2026-05-04 |
| PROMET-BR - Molecular Profiling of Metastatic Prostate Cancer: a Brazilian Cohort (NCT07560215) | AstraZeneca | 2026-04-30 |
| A Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in China (NCT07316062) | AstraZeneca | 2026-04-29 |
| A Study to Investigate NPS and Symptoms in Chinese Adult Participants With CRSwNP Initiating Treatment With Tezepelumab (NCT07520162) | AstraZeneca | 2026-04-24 |
| GYNGHER - HER2 Expression in Gynecological Malignancies: a Brazilian Cohort (NCT07101081) | AstraZeneca | 2026-04-23 |
| Implementation of Standardized Early Identification and Diagnosis for Transthyretin Amyloidosis (ATTR) in High-Risk Populations (NCT07338942) | AstraZeneca | 2026-04-21 |
| MONTEROSA - Italian Multicenter Observational Study to Evaluate Time to Clinical Hepatic Decompensation, Quality of Life, Effectiveness, and Safety of Tremelimumab Plus Durvalumab in Patients With Advanced or Unresectable Hepatocellular Carcinoma Who Have Received no Prior Systemic Treatment. (NCT07607769) | AstraZeneca | 2026-04-16 |
| A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants (NCT07534592) | AstraZeneca | 2026-04-16 |
| A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With Asthma (NCT07525375) | AstraZeneca | 2026-04-14 |
| A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus (NCT07430306) | AstraZeneca | 2026-04-13 |
| A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of AZD4954 and Vice Versa in Healthy Adults (NCT07513571) | AstraZeneca | 2026-04-10 |
| Danicopan PMS in Korea (NCT07457151) | AstraZeneca | 2026-04-10 |
| Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study (NCT07295821) | AstraZeneca | 2026-04-01 |
| Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care System (NCT07361276) | AstraZeneca | 2026-03-31 |
| Observational Study on the Prevalence and Risk Factors of Patients With Hyperkalaemia in Brazil (NCT07370194) | AstraZeneca | 2026-03-31 |
| A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab (NCT07391670) | AstraZeneca | 2026-03-31 |
| A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity. (NCT07511205) | AstraZeneca | 2026-03-30 |
| A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease (NCT07571746) | AstraZeneca | 2026-03-28 |
| A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234 (NCT07546760) | AstraZeneca | 2026-03-20 |
| A Study to Investigate the Clinical Outcome and Quality of Life in Chinese Post-operative CRSwNP Patients (NCT07446738) | AstraZeneca | 2026-03-19 |
| A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Dextromethorphan (CYP2D6 Substrate) in Healthy Participants (NCT07241065) | AstraZeneca | 2026-03-19 |
| NIS to Examine Disease Activity in SLE Patients Treated With Subcutaneous Anifrolumab in Routine Care (NCT07424261) | AstraZeneca | 2026-03-19 |
| A Phase I Study Comparing the Relative Bioavailability of a Fixed-Dose Combination of Laroprovstat/Rosuvastatin vs Their Single Therapy Products in Healthy Adults (NCT07316608) | AstraZeneca | 2026-03-16 |
| A Study to Investigate the Effect of AZD5004 on Mitiglinide and Pioglitazone in Healthy Participants (NCT07444424) | AstraZeneca | 2026-03-13 |
| A Multicenter, Non-interventional, Descriptive Study to Assess Assay Concordance of HER2 IHC Testing in Chinese Pan-tumor Patients (NCT07404202) | AstraZeneca | 2026-03-06 |
| A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma (NCT07433569) | AstraZeneca | 2026-03-05 |
| A Study to Investigate the Pharmacokinetics of Different Formulations and Safety of AZD5004 in Healthy Participants Aged 18 to 55 Years (NCT07455825) | AstraZeneca | 2026-03-05 |
| CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC (NCT07413757) | AstraZeneca | 2026-03-02 |
| A Prospecitve Multicenter, Observational Registry Study (NCT07481526) | AstraZeneca | 2026-02-27 |
| Phase I Study of [111In]-FPI-2107 in EGFR Mutation-positive NSCLC (NCT07500987) | AstraZeneca | 2026-02-27 |
| Lysosomal Acid Lipase Deficiency in Risk Groups (NCT07455864) | AstraZeneca | 2026-02-25 |
| A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics With AZD0780 Following Repeated Dose Administration in Healthy Adults With Elevated LDL-C Levels (NCT07423598) | AstraZeneca | 2026-02-24 |
| A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4) (NCT07391657) | AstraZeneca | 2026-02-23 |